Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib-Reference-Cited by-同舟云学术

Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib

Published:2022-04-17 Issue:20 Volume:11 Page:3743-3750
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Shibaki Ryota¹,Ozawa Yuichi¹^ORCID,Noguchi Susumu²,Murakami Yusuke³,Takase Eri⁴,Azuma Yuichiro⁵,Maebeya Masaru⁶,Sugimoto Takeya¹,Hayata Atsushi¹,Hayakawa Takahiro⁷,Tamaki Shinya⁸,Nakanishi Masanori¹,Teraoka Shunsuke¹,Akamatsu Hiroaki¹

Affiliation:

1. Internal Medicine III Wakayama Medical University Wakayama Japan

2. Respiratory Medicine Japanese Red Cross Wakayama Medical Center Wakayama Japan

3. Respiratory Medicine National Hospital Organization Minami Wakayama Medical Center Wakayama Japan

4. Department of Respiratory Medicine Naga Municipal Hospital Wakayama Japan

5. Respiratory Medicine National Hospital Organization Wakayama Hospital Wakayama Japan

6. Respiratory Medicine Wakayama Rosai Hospital Wakayama Japan

7. Internal Medicine Kinan Hospital Wakayama Japan

8. The Second Department of Internal Medicine Hidaka General Hospital Wakayama Japan

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4750

Reference23 articles.

1. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

2. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

3. Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M–positive NSCLC Treated With Osimertinib in Japan

4. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

5. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is MG53 a potential therapeutic target for cancer?;Frontiers in Endocrinology;2023-11-15

2. Newly diagnosed non‐small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis;Thoracic Cancer;2023-05-26

3. Osimertinib;Reactions Weekly;2022-12-03